Enoxaparin attenuates pyrrolizidine alkaloids‐induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression
Liver International · 2023-03 · 43 (3) · 626-638
DOI: 10.1111/liv.15475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 28.11.2022. Verfasst von Hongyu Xiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Hepatic Veno-Occlusive Disease, Pyrrolizidine Alkaloids. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and Aims The definitive treatment for pyrrolizidine alkaloids (PAs)‐induced hepatic sinusoidal obstruction syndrome (HSOS) is not available. The effectiveness of anticoagulation therapy remains controversial. The efficacy of low molecular weight heparin (LMWH) should be investigated in patients and animal models, and the underlying mechanism should be explored.
Methods
The prognosis of patients with PAs‐HSOS who received anticoagulation therapy was retrospectively analysed. The effect of enoxaparin on the liver injury was determined in animal models of monocrotaline (MCT)‐induced HSOS was determined, and the underlying mechanism was investigated using a murine model.
Results
The cumulative survival rate of patients with PAs‐induced HSOS was 60.00% and 90.90% in the non‐anticoagulation group and anticoagulation group. Enoxaparin attenuated liver injury effectively in a rat model of MCT‐induced HSOS. Additionally, the improvement of severe liver injury was observed in MCT‐treated mice after the administration of enoxaparin (40 mg/kg). The alleviation of liver injury was observed in mice with hepatocyte‐specific deletion of oncostatin M (Osm △Hep ). In MCT‐treated mice administrated with enoxaparin, no significant differences in liver injury were observed between Osm △Hep mice and Osm flox/flox mice. Additionally, adenovirus‐mediated overexpression of Osm resulted in severe liver injury in MCT‐induced mice after the administration of enoxaparin.
Conclusions
LMWH attenuated severe liver injury in patients with PAs‐Induced HSOS and animal models of MCT‐induced HSOS, which provides a rationale for the application of anticoagulation therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xiang, H., Liu, C., Xiao, Z., Du, L., Wei, N., Liu, F., & Song, Y. (2023). Enoxaparin attenuates pyrrolizidine alkaloids‐induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression. Liver International, 43(3), 626-638. https://doi.org/10.1111/liv.15475
Vancouver
Xiang H, Liu C, Xiao Z, Du L, Wei N, Liu F, et al. Enoxaparin attenuates pyrrolizidine alkaloids‐induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression. Liver International. 2023;43(3):626-638. doi:10.1111/liv.15475
BibTeX
@article{Xiang2023,
author = {Xiang, Hongyu and Liu, Chang and Xiao, Zhuanglong and Du, Li and Wei, Ning and Liu, Fang and Song, Yuhu},
title = {Enoxaparin attenuates pyrrolizidine alkaloids‐induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression},
journal = {Liver International},
year = {2023},
volume = {43},
number = {3},
pages = {626--638},
doi = {10.1111/liv.15475}
}
EUVIMED